Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
Citations Over TimeTop 10% of 2022 papers
Abstract
The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited because of innate resistance to treatment. We identified elevated expression of the histone methyltransferase EZH2 as a hallmark of aggressive UCa and hypothesized that EZH2 inhibition, via a small-molecule catalytic inhibitor, might have antitumor effects in UCa. Here, in a carcinogen-induced mouse bladder cancer model, a reduction in tumor progression and an increase in immune infiltration upon EZH2 inhibition were observed. Treatment of mice with EZH2i causes an increase in MHC class II expression in the urothelium and can activate infiltrating T cells. Unexpectedly, we found that the lack of an intact adaptive immune system completely abolishes the antitumor effects induced by EZH2 catalytic inhibition. These findings show that immune evasion is the only important determinant for the efficacy of EZH2 catalytic inhibition treatment in a UCa model.
Related Papers
- → Mechanisms of Disease: involvement of the urothelium in bladder dysfunction(2007)351 cited
- → Upper Urinary Tract Transitional Cell Carcinoma(2008)7 cited
- → Detection of neoplastic and preneoplastic urothelia by combined scanning and transmission electron microscopy of urinary surface of human and rat bladders(1977)48 cited
- → Adrenergic α1A receptor modulates cultured urothelium structure(2007)1 cited
- Adipose-derived stem cells can be induced into urothelium-like phenotype in vitro by indirect co-culture with porcine urothelium cells(2012)